Who can participate?

Inclusion Criteria:

• Diagnosis of one of the following:
  
  • Acute myeloid leukemia (AML)
  • Acute undifferentiated leukemia (AUL)
  • Mixed phenotype acute leukemia (MPAL)
  • T-cell acute lymphoblastic leukemia (T ALL)
  • Early thymocyte precursor (ETP) ALL
  • KMT2A-rearranged ALL
• Disease Status
  
  • Relapsed/Refractory AML, MPA, and AUL
  • Untreated therapy related AML
  • Relapsed/Refractory KMT2A-rearranged ALL, T-cell ALL, ETEP ALL
• Karnofsky/Lanksy performance level score of greater than or equal to 50 percent.
• Prior therapy requirements
  
  • Fully recovered from acute toxicities of Hematopoietic Stem Cell Transplant (HSCT) or Anthracycline Exposure
  • 14 days must have elapsed since the completion of systemic cytotoxic therapy other than hydroxyurea, decitabine or azacitidine
  • 2 weeks must have elapsed for local palliative radiotherapy (RT); 6 months must have elapsed if prior craniospinal RT or if 50% radiation of pelvis, and at least 6 weeks must have elapsed if other substantial bone marrow radiation
• Adequate renal, liver, cardiac, and central nervous system (CNS) function

Exclusion Criteria:

• Diagnosis of one of the following:
  
  • Acute Promyelocytic Leukemia (APML)
  • Acute leukemia with CNS status 3 involvement
  • Philadelphia chromosome positive leukemia (Ph+ ALL, MPAL, or AUL)
  • Fanconi Anemia, Shwachman-Diamond syndrome, or any other bone marrow failure syndrome or DNA repair disorder
  • Wilson’s Disease or other copper-metabolism disorder
• Pregnant or breastfeeding
• Uncontrolled infection
• Received greater than 13.6 Gray (Gy) prior radiation to the mediastinum
• Unable to swallow tablets
• Receipt of growth factors within 7 days prior to enrollment
• Currently receiving another investigational drug
• Currently receiving anti-cancer agents (with the exception of intrathecal (IT) agents or hydroxyurea)
• Unable to comply with the safety monitoring requirements of the study